Trial Profile
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3 Efficacy and Safety Study of Benralizumab (MEDI-563) to Reduce Oral Corticosteroid Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus Long-acting β2 Agonist and Chronic Oral Corticosteroid Therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Jul 2023
Price :
$35
*
At a glance
- Drugs Benralizumab (Primary)
- Indications Asthma
- Focus Registrational; Therapeutic Use
- Acronyms ZONDA
- Sponsors AstraZeneca
- 24 May 2023 Results of an analysis assessing rates of clinical remission after treatment with benralizumab in patients with SEA with or without CRSwNP from 5 clinical studies (SIROCCO, CALIMA, ZONDA, ANDHI and PONENTE) presented at the 119th International Conference of the American Thoracic Society
- 14 Mar 2022 Results of post-hoc pooled analysis assessing composite remission definition to characterize individual responses to benralizumab after 6 and 12 months in 3 phase III studies (SIROCCO (NCT01928771); CALIMA (NCT01914757); ZONDA (NCT02075255)) were published in the Advances in Therapy.
- 21 Oct 2020 Results of post-hoc analysis assessing fficacy of benralizumab in reducing AER for patients with and without early clinically meaningful improvements above baseline in pre-bronchodilator FEV1, presented at the CHEST Annual Meeting 2020 by Annual Meeting of the American College of Chest Physicians.